Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Sercan
dc.contributor.authorAdas, Yasemin Guzle
dc.contributor.authorHicsonmez, Ayse
dc.contributor.authorAndrieu, Meltem Nalca
dc.contributor.authorAkyurek, Serap
dc.contributor.authorGokce, Saban Cakir
dc.date.accessioned2024-04-24T17:28:18Z
dc.date.available2024-04-24T17:28:18Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Concurrent chemo-radiotherapy is the recommended standard treatment modality for patients with locally advanced lung cancer. The purpose of three-dimensional conformal radiotherapy (3DCRT) is to minimize normal tissue damage while a high dose can be delivered to the tumor. The most common dose limiting side effect of thoracic RT is radiation pneumonia (RP). In this study we evaluated the relationship between dose-volume histogram parameters and radiation pneumonitis. This study targeted prediction of the possible development of RP and evaluation of the relationship between dose-volume histogram (DVH) parameters and RP in patients undergoing 3DCRT. Materials and Methods: DVHs of 41 lung cancer patients treated with 3DCRT were evaluated with respect to the development of grade >= 2 RP by excluding gross tumor volume (GTV) and planned target volume (PTV) from total (TL) and ipsilateral (IPSI) lung volume. Results: Were admitted statistically significant for p<0.05. Conclusions: The cut-off values for V5, V13, V20, V30, V45 and the mean dose of TL-GTV; and V13, V20, V30 and the mean dose of TL-PTV were statistically significant for the development of Grade >= 2 RP. No statistically significant results related to the development of Grade >= 2 RP were observed for the ipsilateral lung and the evaluation of PTV volume. A controlled and careful evaluation of the dose-volume histograms is important to assess Grade >= 2 RP development of the lung cancer patients treated with concurrent chemo-radiotherapy. In the light of the obtained data it can be said that RP development may be avoided by the proper analysis of the dose volume histograms and the application of optimal treatment plans.en_US
dc.identifier.doi10.7314/APJCP.2014.15.17.7371
dc.identifier.endpage7375en_US
dc.identifier.issn1513-7368
dc.identifier.issue17en_US
dc.identifier.pmid25227844
dc.identifier.startpage7371en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.17.7371
dc.identifier.urihttps://hdl.handle.net/11468/20395
dc.identifier.volume15en_US
dc.identifier.wosWOS:000343833100064
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung Canceren_US
dc.subjectRadiotherapyen_US
dc.subjectRadiation Pneumonitisen_US
dc.subjectPreventionen_US
dc.titleEvaluation of the Radiation Pneumonia Development Risk in Lung Cancer Casesen_US
dc.titleEvaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu